Literature DB >> 15104254

Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody.

Jialiang Hu1, Philippe E Van den Steen, Michel Houde, T Toney Ilenchuk, Ghislain Opdenakker.   

Abstract

Matrix metalloproteinases form a proteinase family with at least 20 members, which are involved in several pathological conditions and which fulfill a large number of physiological functions. Gelatinase A/MMP-2 is a constitutively produced homeostatic enzyme, whereas gelatinase B/MMP-9 is upregulated in acute and chronic inflammations and forms a target for the development of therapeutic inhibitors. We have used a recently developed assay with fluorescent gelatin to analyze gelatinase inhibitors. A peptidomimetic, based on the consensus sequence of the cleavage sites in type II collagen, and various derivatives of a neutralizing antibody were compared as gelatinase inhibitors. A single-chain variable fragment (scFv) derived from the gelatinase B-selective monoclonal antibody REGA-3G12 was tagged with oligohistidine and was also compared with the untagged scFv. Both scFv derivatives inhibited gelatinase B but the peptidomimetic was inefficient. As an extra control and serendipitously it was found that polyhistidine is an inhibitor of gelatinases, presumably by altering the active site by chelation of the catalytic Zn2+.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104254     DOI: 10.1016/j.bcp.2003.10.030

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 2.  Is there new hope for therapeutic matrix metalloproteinase inhibition?

Authors:  Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Nat Rev Drug Discov       Date:  2014-11-07       Impact factor: 84.694

3.  Fusion Peptides CPU1 and CPU2 Inhibit Matrix Metalloproteinases and Protect Mice from Endotoxin Shock Within a Strict Time Window.

Authors:  Zheng Qiu; Fengguo Zhang; Chengxin Gong; Hanmei Xu; Jialiang Hu
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

4.  Zymography as a Research Tool in the Study of Matrix Metalloproteinase Inhibitors.

Authors:  Zongli Ren; Juanjuan Chen; Raouf A Khalil
Journal:  Methods Mol Biol       Date:  2017

5.  Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.

Authors:  Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Lillian Onwuha-Ekpete; Kelli Harmon; Trista Robichaud; Rita Fuerst; Roma Stawikowska; Bjorn Steffensen; William Roush; Hector R Wong; Gregg B Fields
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

Review 6.  Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.

Authors:  Nabil M Abdel-Hamid; Shimaa A Abass
Journal:  Mol Biol Rep       Date:  2021-08-11       Impact factor: 2.316

Review 7.  High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy.

Authors:  Yujian Zhang; Ira Pastan
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

8.  The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells.

Authors:  Małgorzata Kapral; Joanna Wawszczyk; Magdalena Jurzak; Andrzej Hollek; Ludmiła Węglarz
Journal:  Int J Colorectal Dis       Date:  2012-03-15       Impact factor: 2.571

Review 9.  New strategies for targeting matrix metalloproteinases.

Authors:  Gregg B Fields
Journal:  Matrix Biol       Date:  2015-01-14       Impact factor: 11.583

10.  Nucleic acid-induced potentiation of matrix metalloproteinase-9 enzymatic activity.

Authors:  Tyler Duellman; Xi Chen; Rie Wakamiya; Jay Yang
Journal:  Biochem J       Date:  2018-05-09       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.